Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 7/20 | 0.40 |
| ▸ | BRD9 | Q9H8M2 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | LPL | P06858 | 5/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.33 |
| ▸ | F11 | P03951 | 2/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22325994 | 0.90 | BRD4 (0.37) | BRD4BRD9CA1CA2CA9 | |
| SCHEMBL29848701 | 0.89 | BRD4 (0.34) | BRD4BRD9CA1CA2CA9 | |
| SCHEMBL29948355 | 0.89 | CA1 (0.34) | BRD4BRD9CA1CA2CA9 | |
| SCHEMBL16651646 | 0.85 | CA1 (0.36) | BRD4CA1CA2CA9IDO1 | |
| SCHEMBL23001755 | 0.82 | CA1 (0.36) | CA1CA2CA9IDO1TDO2 | |
| SCHEMBL21224665 | 0.82 | AURKA (0.40) | BRD4CA1CA2CA9IDO1 | |
| SCHEMBL22339403 | 0.82 | LPL (0.34) | CA1CA2CA9IDO1TDO2 | |
| SCHEMBL16650516 | 0.82 | LPL (0.40) | CA1CA2CA9IDO1TDO2 | |
| SCHEMBL18496375 | 0.81 | LIPG (0.38) | CA1CA2CA9IDO1TDO2 | |
| SCHEMBL16650743 | 0.80 | LPL (0.33) | CA1CA2CA9IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107371-A2 | INDOLYL-PYRIDINONES AND RELATED COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260098028-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-04-09 | — | — | US | disclosed |
| US-12558341-B2 | Oral complement factor D inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260008778-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
| EP-4674484-A2 | THIENOPYRROLE COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-12497392-B2 | EP300/CBP inhibitor | HINOVA PHARMACEUTICALS INC. (CN) | 2025-12-16 | — | — | US | disclosed |
| US-12497395-B2 | Small molecule bromodomain inhibitors and uses therof | CONVERGENE, LLC | 2025-12-16 | — | — | US | disclosed |
| US-12441711-B2 | Compounds and their use for treatment of hemoglobinopathies | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-10-14 | — | — | US | disclosed |
| EP-4291562-B1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-4612128-A1 | COMPOUNDS AND THEIR USE FOR TREATMENT OF HEMOGLOBINOPATHIES | Bristol-Myers Squibb Company (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20140288048-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2014-09-25 | — | — | US | disclosed |
| US-20140288048-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2014-09-25 | — | — | US | disclosed |
| US-8785470-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785470-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| EP-2751093-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Infinity Pharmaceuticals, Inc. (US) | 2014-07-09 | — | — | EP | disclosed |
| US-20140100214-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. (US) | 2014-04-10 | — | — | US | disclosed |
| WO-2013032591-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013032591-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20130053362-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLKINE, LLC (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053362-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLKINE, LLC (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288048-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AKT3, PIK3CA, AKT1 | BRD4 1018/4885BRD9 1767/4885CA1 2993/4885 |
| US-20130053362-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AKT3, PIK3CA, AKT1 | BRD4 1018/4885BRD9 1767/4885CA1 2993/4885 |
| US-12497392-B2 | EP300/CBP inhibitor | EP300, MLLT1, CREBBP | BRD4 11/4885BRD9 17/4885CA1 2938/4885 |
| US-20140100214-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AKT3, PIK3CA, AKT1 | BRD4 1018/4885BRD9 1767/4885CA1 2993/4885 |
| US-12497395-B2 | Small molecule bromodomain inhibitors and uses therof | BRD4, BRPF3, BICRA | BRD4 1/4885BRD9 18/4885CA1 4765/4885 |
| US-12558341-B2 | Oral complement factor D inhibitors | CFD, CFH, CFB | BRD4 3880/4885BRD9 1393/4885CA1 3369/4885 |
| US-12441711-B2 | Compounds and their use for treatment of hemoglobinopathies | HBG1, HBG2, HBB | BRD4 3763/4885BRD9 3992/4885CA1 4815/4885 |
| US-20260098028-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | HBZ, HBG2, HBB | BRD4 4085/4885BRD9 3066/4885CA1 2066/4885 |
| US-20260008778-A1 | COMPOUNDS AND USES THEREOF | BRD9, BCL9L, BCL9 | BRD4 127/4885BRD9 1/4885CA1 3761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.